Zhang Yihan, Wu Yunhao, Liu Zixu, Yang Kangping, Lin Hui, Xiong Kai
Department of Gastroenterology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330008, Jiangxi, China.
The Second School of Clinical Medicine, Jiangxi Medical College, Nanchang, China.
Cancer Cell Int. 2024 Oct 1;24(1):333. doi: 10.1186/s12935-024-03516-w.
Metformin, a widely used oral hypoglycemic drug, has emerged as a potential therapeutic agent for cancer treatment. While initially known for its role in managing diabetes, accumulating evidence suggests that metformin exhibits anticancer properties through various mechanisms. Several cellular or animal experiments have attempted to elucidate the role of non-coding RNA molecules, including microRNAs and long non-coding RNAs, in mediating the anticancer effects of metformin. The present review summarized the current understanding of the mechanisms by which non-coding RNAs modulate the response to metformin in cancer cells. The regulatory roles of non-coding RNAs, particularly miRNAs, in key cellular processes such as cell proliferation, cell death, angiogenesis, metabolism and epigenetics, and how metformin affects these processes are discussed. This review also highlights the role of lncRNAs in cancer types such as lung adenocarcinoma, breast cancer, and renal cancer, and points out the need for further exploration of the mechanisms by which metformin regulates lncRNAs. In addition, the present review explores the potential advantages of metformin-based therapies over direct delivery of ncRNAs, and this review highlights the mechanisms of non-coding RNA regulation when metformin is combined with other therapies. Overall, the present review provides insights into the molecular mechanisms underlying the anticancer effects of metformin mediated by non-coding RNAs, offering novel opportunities for the development of personalized treatment strategies in cancer patients.
二甲双胍是一种广泛使用的口服降糖药，已成为一种潜在的癌症治疗药物。虽然最初因其在治疗糖尿病中的作用而闻名，但越来越多的证据表明，二甲双胍通过多种机制展现出抗癌特性。一些细胞或动物实验试图阐明非编码RNA分子，包括微小RNA和长链非编码RNA，在介导二甲双胍抗癌作用中的作用。本综述总结了目前对非编码RNA调节癌细胞对二甲双胍反应机制的理解。讨论了非编码RNA，特别是微小RNA在细胞增殖、细胞死亡、血管生成、代谢和表观遗传学等关键细胞过程中的调节作用，以及二甲双胍如何影响这些过程。本综述还强调了长链非编码RNA在肺腺癌、乳腺癌和肾癌等癌症类型中的作用，并指出需要进一步探索二甲双胍调节长链非编码RNA的机制。此外，本综述探讨了基于二甲双胍的疗法相对于直接递送非编码RNA的潜在优势，并强调了二甲双胍与其他疗法联合使用时非编码RNA的调节机制。总体而言，本综述深入探讨了非编码RNA介导的二甲双胍抗癌作用的分子机制，为癌症患者个性化治疗策略的开发提供了新的机会。
